However, unlike BRCA1 or BRCA2 mutation carriers who may have field cancerization changes, in the high risk preinvasive breast conditions such as ductal carcinoma in situ, one must assess concordance between pretreatment core biopsy generally taken from within the center of the lesion and the residual tissue resected in the final surgery [64]. Here, BRCA2 is linked to ductal breast carcinoma in situ.